|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were 14 cases (14.29%, 14/98) and 34 cases (34.70%, 34/98) of lymphomas with the DHL and DEL of MYC and BCL2/BCL6, respectively.
|
31615842 |
2020 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide a rationale for dual targeting of BRD4 and BCL2 using AZD5153 and AZD4320 as a therapeutic strategy against DHL and DEL.
|
29931583 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore examined the role of XPO1 as a therapeutic target in suppressing MYC function and the potential synergistic effects of simultaneous suppression of XPO1 and BCL2 in the treatment of DHL.
|
31752970 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones displaying loss of 18q21 amplicons that harbor BCL2.
|
31085176 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of c<i>-Myc</i>, <i>BCL2, BCL6</i> gene rearrangements were 5.8%, 5.8%, and 14.2%, respectively; and 1.6% were Double Hit Lymphoma (DHL).
|
31171907 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A considerable proportion of relapsed or refractory large B cells belong to the WHO subtype known as high-grade B-cell lymphoma with rearrangement of MYC and BCL2 and/or BCL6, also known as double-hit lymphoma (DHL).
|
29419530 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dual translocation of MYC and BCL2 or the dual overexpression of these proteins in patients with aggressive B-cell lymphomas (termed double-hit lymphoma [DHL] and double-expressor lymphoma [DEL], respectively) have poor outcomes after chemoimmunotherapy with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
|
30707764 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
|
31288832 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted approaches, especially chimeric antigen receptor T-cell therapies and small-molecule inhibitors targeting myc or bcl-2, exhibit the potential of improving outcomes for patients with DHL.
|
31117849 |
2019 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, inhibition of PLK1 triggered degradation of MYC and of the antiapoptotic protein MCL-1, and PLK1 inhibitors showed synergy with BCL-2 antagonists in blocking DHL cell growth, survival, and tumorigenicity, supporting clinical targeting of PLK1 in DHL.
|
30260324 |
2018 |
|
Double-Hit Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations.
|
29310838 |
2018 |
|
Double-Hit Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Double-hit lymphoma (DHL), defined as a dual rearrangement of MYC and BCL2 and/or B-cell CLL/lymphoma 6 (BCL6) genes, is an uncommon subset accounting for 5% to 7% of all diffuse large B-cell lymphomas (DLBCLs), and long-term survivors are rare.
|
30252929 |
2018 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnosing double hit lymphoma requires identification of translocations of MYC and BCL2 and/or BCL6.
|
30213392 |
2018 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these findings highlight the relevance of BFL-1 in DH lymphoma-associated drug resistance and support the combined use of a BCL-2 antagonist and a BET inhibitor as a promising therapeutic strategy for patients with aggressive DHL.
|
29353886 |
2018 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PLK1 inhibition with volasertib, alone and in combination with the BCL-2 inhibitor venetoclax, was efficacious in multiple DHL models, including mice harboring DHL patient-derived xenografts.
|
30395539 |
2018 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with B cell lymphomas bearing MYC translocation combined with translocation involving other genes, such as BCL2, BCL3, or BCL6, defined as double-hit lymphoma (DHL), have a poor prognosis.
|
28595585 |
2017 |
|
Double-Hit Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sixty-seven (33%) cases were P53 positive, 56 (28%) had MYC-R (including 17 MYC/BCL2 double hit lymphoma), 86 (45%) were MYC+/BCL2+, and 47 (24%) were positive for both MYC and P53.
|
27739436 |
2017 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied the clinicopathological features and outcome of 13 patients with MYC/BCL6 DHL and compared this group to a group of 83 MYC/BCL2 DHL patients.
|
26426741 |
2016 |
|
Double-Hit Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 117 patients were included in the current analysis (76 BCL2-DHL patients, 16 BCL6-DHL patients, and 25 THL patients).
|
26565895 |
2016 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective study, we assess 157 patients with MYC/BCL2 DHL including 108 patients with de novo disease and 49 patients with a history of FL or rarely other types of low-grade B-cell lymphoma.
|
27203548 |
2016 |
|
Double-Hit Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture.
|
27913503 |
2016 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, patients with SHL have distinct clinicopathologic features but a similar poor prognosis compared with patients with MYC/BCL2 DHL.
|
26448193 |
2016 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Double-hit lymphoma is characterized by the presence of concurrent MYC (myelocytomatosis oncogene) and BCL2 (B-cell lymphoma 2) gene rearrangements.
|
25656914 |
2015 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In aggregate, these results support expanding the category of MYC/BCL2 DHL to include large B-cell lymphomas with coexistent MYC and BCL2 abnormalities other than concurrent translocations.
|
25103070 |
2015 |
|
Double-Hit Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC/BCL2 double-hit lymphoma (DHL), defined by conventional cytogenetic or fluorescence in situ hybridization (FISH) analysis, and MYC/BCL2 double-positive lymphoma (DPL), defined by immunohistochemistry, are associated with a poor prognosis.
|
25828389 |
2015 |